The Diversity of Drug Statutes Regarding Scientific Advances: How to Categorise a Culture Supernatant for Health Security Reasons journal article Laure Fourrier, Sylvain Perruche, Mathieu Guerriaud European Pharmaceutical Law Review, Volume 3 (2019), Issue 3, Page 107 - 115 Given the speed of developments in the pharmaceutical sector it is perhaps no surprise that legal frameworks struggle to keep apace. In fact, nowadays, researchers produce more and more drugs that cannot be easily categorised according to the existing legal statuses. This is particularly true for a very promising cell supernatant, which is difficult to fit into existing categories. This article illustrates the difficulties related to the classification of such a supernatant and proposes necessary changes to the current EU legal statuses of medicinal products.
Are You AI’S Favourite? EU Legal Implications of Biased AI Systems in Clinical Genetics and Genomics Anastasiya Kiseleva, Paul Quinn
A Case of Unforeseen Adverse Side-Effects? The Ireland/Northern Ireland Protocol and Medicines Regulation George Peretz, Xisca Borrás